[1]
Wang Y, Hussain SM, Wluka AE, et al. Association between metformin use and disease progression in obese people with knee osteoarthritis: Data from the Osteoarthritis Initiative - A prospective cohort study. Arthritis Res Ther 2019; 21(1): 1-6.
[2]
Lotz M, Martel-Pelletier J, Christiansen C, et al. Value of biomarkers in osteoarthritis: Current status and perspectives. Postgrad Med J 2014; 90(1061): 171-8.
[3]
Sokolove J, Lepus CM. Role of inflammation in the pathogenesis of osteoarthritis: Latest findings and interpretations. Ther Adv Musculoskelet Dis 2013; 5(2): 77-94.
[4]
Cicuttini FM, Baker Jr ST. The association of obesity with osteoarthritis of the hand and knee in women: a twin study. J Rheumatol 1996; 23: 1221-6.
[5]
Conde J, Scotece M, Gómez R, Lopez V, Gómez-Reino JJ, Gualillo O. Adipokines and osteoarthritis: Novel molecules involved in the pathogenesis and progression of disease. Arthritis 2011; 2011: 1-8.
[6]
Kroon FPB, Veenbrink AI, de Mutsert R, et al. The role of leptin and adiponectin as mediators in the relationship between adiposity and hand and knee osteoarthritis Osteoarthr Cartil[Internet] 2019; Available from:. https://linkinghub.elsevier.com/retrieve/pii/S1063458419311732
[7]
Han W, Aitken D, Zheng S, et al. Higher Serum Levels of Resistin Are Associated With Knee Synovitis and Structural Abnormalities in Patients With Symptomatic Knee Osteoarthritis. J Am Med Dir Assoc 2019; 20(10): 1242-6.
[8]
Dumond H, Presle N, Terlain B, et al. Evidence for a Key Role of Leptin in Osteoarthritis. Arthritis Rheum 2003; 48(11): 3118-29.
[9]
Poonpet T, Honsawek S. Adipokines: Biomarkers for osteoarthritis? World J Orthop 2014; 5(3): 319-27.
[10]
Aitken D, Laslett LL, Pan F, et al. A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis - the HUMOR trial. Osteoarthr Cartil [Internet] 2018; 26(7): 880-7.[Available from]..
[http://dx.doi.org/10.1016/j.joca.2018.02.899]
[http://dx.doi.org/10.1016/j.joca.2018.02.899]
[11]
Chevalier X, Ravaud P, Maheu E, et al. Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: A randomised, multicentre, double-blind, placebo-controlled trial. Ann Rheum Dis 2015; 74(9): 1697-705.
[12]
Kloppenburg M, Ramonda R, Bobacz K, et al. Etanercept in patients with inflammatory hand osteoarthritis (EHOA): A multicentre, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2018; 77(12): 1757-64.
[13]
Robertson CR, Rice Jr AN. Treatment of erosive osteoarthritis with hydroxychloroquine. Arthritis Rheum 1993; 36(Suppl.): S167.
[14]
Müller-Ladner U. Raynaud’s Phenomenon and Peripheral Ischemic Syndromes. 1st ed. Bremen: UNI-MED Verlag AG; 2008; 2008. 18–30 p..
[15]
Bryant LR, des Rosier KFCM. Hydroxychloroquine in the treatment of erosive osteoarthritis. J Rheumatol 1995; 22(8): 1527-31.
[16]
Kingsbury SR, Tharmanathan P, Keding A, et al. Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis a randomized trial. Ann Intern Med 2018; 168(6): 385-95.
[17]
Funck-Brentano T, Cohen-Solal M. Subchondral bone and osteoarthritis. Curr Opin Rheumatol 2015; 27(4): 420-6.
[18]
Lems WF. Bisphosphonates: A therapeutic option for knee osteoarthritis? Ann Rheum Dis 2018; 77(9): 1247-8.
[19]
Mohammed MM, Mohammed MM, Al-shamma K, Jasim NA. Evaluation of the anti-inflammatory effect of metformin as adjuvant therapy to NSAID (Meloxicam) in patients with knee osteoarthritis. Int J Sci Nat 2014; 5(2): 277-82.
[20]
Mohammed MM, Al-Shamma KJ, Jassim NA. Evaluation of the clinical use of metformin or pioglitazone in combination with meloxicam in patients with knee osteoarthritis. Iraqi J Pharm Sci 2014; 23(2): 13-23.
Related Books
Natural Products for the Management of Arthritic Disorders
Article Metrics
11